In Silico Screening of Effective Inhibitor of 5α-Reductase Type 1 for Androgenic Alopecia Treatment

This article reviews the effects of 5 alpha-reductase inhibitors for treating conditions like male pattern baldness and benign prostatic hyperplasia, noting significant DHT reduction but reports no new clinical results.

This study established that a human epidermal model can be utilized to assess 5alpha-reductase activity and evaluate enzyme modulators, such as finasteride, for dermatological applications.

This study synthesized and evaluated hydroxycinnamate derivatives for their ability to inhibit human SRD5A1, finding that three compounds showed significant inhibitory activity and low cytotoxicity. Compound 10a notably reduced SRD5A1 protein expression in cells, suggesting potential for nonsteroidal treatment of androgen-related conditions.

In this study using a virtual screening approach, eriocitrin and silymarin were identified as potent flavonoid compounds that strongly and stably interacted with 5α-reductase type II, suggesting potential development as novel treatments for androgenic alopecia.

This study reports that taxifolin from enzymatic hydrolysis effectively regulates dermal papilla cell apoptosis and promotes hair growth by increasing IGF-1 and reducing TGF-β1, though it shows less inhibition of DHT compared to minoxidil.